Table 2.
Clinical Characteristics of RA Patients Grouped by PAD4 T Cell Statusa
| total (n = 19) |
group 1 T cell negative (n = 14) |
group 2 T cell positive (n = 5) |
group 1 vs group 2 p-value |
|
|---|---|---|---|---|
| gender, % female | 58 | 57 | 60 | 0.99 |
| raceb, % caucasian | 94 (n = 18) | 92 (n = 13) | 100 | 0.99 |
| age, mean years ± SD | 64 ±9 | 64 ± 10 | 65 ± 7 | 0.82 |
| RA duration, years | 18 (13−28) | 17 (13−30) | 19 (14−20) | 0.59 |
| DR1 positive, % | 74 | 71 | 80 | 0.99 |
| DR4 positive, % | 63 | 50 | 100 | 0.11 |
| DR1 and DR4 positive, % | 42 | 29 | 80 | 0.11 |
| anti-CCP, % | 100 | 100 | 100 | 0.99 |
| anti-CCPb, units | 100 (64−160) (n = 18) | 100 (64−160) (n = 13) | 100 (96−122) | 0.92 |
| anti-PAD4, % | 63 | 64 | 60 | 0.99 |
| CRPb, mg/L | 0.8 (0.4−1.6) (n = 17) | 0.6 (0.4−1.0) (n = 13) | 2.1 (1.2−3.2) (n = 4) | 0.042 |
| CDAI scoreb | 6.0 (1.0−9.5) (n = 15) | 5.6 (1.0−11.0) (n = 12) | 6.0 (1.3−6.0) (n = 3) | 0.77 |
| prednisoneb, % | 24 (n = 17) | 23 (n = 13) | 25 (n = 4) | 0.99 |
| nonbiologic DMARDsb, % | 76 (n = 17) | 77 (n = 13) | 75 (n = 4) | 0.99 |
| biologic DMARDsb, % | 76 (n = 17) | 69 (n = 13) | 100 (n = 4) | 0.52 |
a
Median (interquartile range) depicted unless otherwise noted.
b
Only patients with available data were included; n is indicated.
Anti-CCP = anticyclic citrullinated peptide antibodies; CDAI = clinical disease activity index; CRP = C-reactive protein; DMARDs = disease-modifying antirheumatic drugs including nonbiologic (methotrexate, sulfasalazine, leflunomide, and/or hydroxychloroquine) and biologic (monoclonal antibody inhibitors of TNFα, IL-6, or T cell costimulation); SD = standard deviation.